Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., listed on Nasdaq under ticker DECA, filed a Form 10-Q with the SEC on August 19, 2024, reflecting its status as a post-combination operating company in the biopharmaceutical sector. Semnur completed its business combination with Decathlon Acquisition Corp., a blank-check company that went public in 2021 targeting the healthcare and life sciences space. Semnur's pipeline is focused on novel pain management therapeutics, with its lead candidate addressing lumbosacral radicular pain. The quarterly filing documents the company's financial position and operational progress as it advances through its clinical and commercial development programs under the DECA ticker. Sign up on SpacDesk for full transaction history, filing timelines, and real-time deal data on DECA and hundreds of other SPAC combinations.